Home 2017-05-04T15:26:22+00:00

IN THE NEWS
1705, 2017

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema - Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema PALO ALTO, Calif., May 17, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies of ubenimex in which modulation of the inflammatory mediator, leukotriene B4 (LTB4), improved experimental lymphedema.  Targeted reduction of LTB4 with ubenimex reversed edema, improved lymphatic function and restored [...]

1505, 2017

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension - Phase 2 LIBERTY Data Expected First Quarter 2018 PALO ALTO, Calif., May 15, 2017 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 LIBERTY study.  The LIBERTY study is designed to evaluate the effects of ubenimex added to current standard of care in patients with [...]

1205, 2017

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results — Five Phase 2 Programs in Four Orphan Indications Progressing — Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif., May 12, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three months ended March 31, 2017 and provided a business update. “Building on our achievements in 2016, we have continued to execute on all programs [...]